Pennant (PNTG) Q2 2026 earnings review
Massive Volume Growth Masks Underlying Unit Price Compression
Pennant delivered a blowout quarter fueled by the integration of the UnitedHealth/Amedisys assets and strong organic volume. Total revenue surged 35.8% YoY to $298.0M, while Adjusted EBITDA jumped 48.2% to $24.3M. The Home Health & Hospice segment drove the bulk of the growth, with home health admissions accelerating by 62.3% YoY. However, beneath the impressive headline volume, per-episode Medicare revenue actually contracted. Management's confidence is high, leading to an updated full-year FY26 revenue guidance midpoint of $1.18B, but investors must weigh exceptional operational execution against a challenging reimbursement environment.
🐂 Bull Case
The massive integration of 50+ UnitedHealth/Amedisys locations is outperforming expectations. Transitioning the two largest waves by mid-Q4 de-risks the back half of the year and provides a massive volume tailwind.
Same-store home health admissions grew 9.7% YoY, and same-store hospice ADC grew 10.8% YoY. The company is actively taking market share in existing territories.
🐻 Bear Case
Average Medicare revenue per 60-day home health episode dropped 1.9% YoY. The company is working harder just to maintain unit economics.
GAAP Net Income grew only 28.2% (vs 48.2% for Adj EBITDA), heavily weighed down by real cash expenses like $1.25M in TSA (Transition Services Agreement) costs that are adjusted out of headline metrics.
⚖️ Verdict: 🟢
Bullish. Pennant is flawlessly executing one of the most complex M&A integrations in its history while simultaneously expanding Adjusted EBITDA margins and driving high-single-digit organic growth.
Key Themes
Southeast Expansion & HCHB Technology Integration
The integration of the UnitedHealth/Amedisys portfolio is the primary growth engine. Management noted the transition is unfolding 'ahead of our expectations.' A critical piece of this success is the migration of these newly acquired agencies onto Pennant's standard Homecare Homebase (HCHB) clinical and financial operating system. This technology transition allows local leaders to tap into Pennant's shared services organization, directly expanding margins.
Senior Living Pricing Power
The Senior Living segment continues its steady march upward, driven heavily by pricing power. Same-store average monthly revenue per occupied room (RevPOR) accelerated by 5.5% YoY to $5,413. This pure margin expansion helped drive a 13.2% YoY increase in segment Adjusted EBITDA, proving the turnaround in this segment has structural durability.
Home Health Market Share Capture
Volume is exploding. Total home health admissions skyrocketed 62.3% YoY. Even stripping out the M&A noise, same-store total Medicare admissions grew 13.6% YoY. This indicates Pennant's localized, cluster-based leadership model is successfully stripping referral volume away from regional competitors.
Macro: Contradictory Narrative on Medicare Reimbursement
Management stated the company is positioned to 'benefit from the more stable payment landscape that appears ahead.' However, the actual reported data contradicts this optimistic narrative. Total agency Average Medicare revenue per 60-day completed episode fell 1.9% YoY to $3,716 (and is down 1.5% YTD). This is a reversing trend that proves CMS rate cuts are actively eroding unit economics. Pennant is offsetting this entirely through volume, but the unit-level pricing environment is anything but stable.
Senior Living Occupancy Reversing from Peak
While RevPOR is growing, occupancy momentum has stalled. Same-store occupancy for Q2 2026 was 81.6%. While this is up 150 bps YoY, it represents a sequential deceleration/reversing trend compared to the 81.8% achieved in Q3 2025 and 82.1% in Q4 2025. If occupancy has structurally plateaued in the low 80s, future segment EBITDA growth will rely entirely on pushing price increases onto residents.
Real Cash Drain from TSA and Restructuring
The gap between GAAP and Non-GAAP metrics remains wide. During Q2, the company incurred $2.49M in Transition Services Agreement (TSA) fees paid to UnitedHealth, adjusting out $1.25M as 'redundant or non-recurring.' While standard practice in carve-outs, these are real cash outflows dragging on operating cash generation during the transition period.
Other KPIs
Accelerating. Up from $13.4 million in the prior year period. This is an essential metric to monitor, as the company needs robust internal cash generation to fund the elevated working capital requirements and integration costs of the UHG/Amedisys asset absorption without over-leveraging the balance sheet.
Accelerating. Up an impressive 47.9% YoY. Rent costs for this segment increased by only $1.0M YoY to $3.2M, meaning the vast majority of gross profit is flowing directly through to the segment operating line, showcasing massive operating leverage as volume scales.
Guidance
Decelerating slightly from the current quarter's 35.8% YoY pace, but still represents massive ~24.5% implied annual growth over FY25's $947.7M. The guide explicitly includes $196-$198M directly from the UnitedHealth/Amedisys assets.
Stable. Represents ~32.7% implied YoY growth over FY25's $72.5M. The UnitedHealth/Amedisys assets are expected to contribute $17.0-$18.6M of this total, proving that despite integration costs, the acquired assets are solidly accretive to the bottom line within year one.
Accelerating trajectory year-over-year. The midpoint of $1.375 implies a 16.5% increase over FY25's $1.18. This accounts for a higher share count (~37.0M diluted shares vs ~35.7M in FY25) used to fund the recent aggressive acquisition phase.
Key Questions
Medicare Rate Defense
Total agency Average Medicare revenue per 60-day episode dropped 1.9% YoY. How much of this is driven by pure rate cuts versus a structural change in patient acuity mix, and what is the floor for unit economics?
Senior Living Occupancy Ceiling
Same-store senior living occupancy came in at 81.6%, trailing the highs of late 2025 (82.1%). Has the portfolio reached a structural occupancy ceiling, shifting the burden of growth entirely to pricing?
TSA Run-Rate Exhaustion
You incurred nearly $2.5M in TSA fees in Q2 for the UHG/Amedisys integration. As the final waves transition in Q4, exactly when in late FY26 or early FY27 should investors expect these cash drains to hit zero?